Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
HIV-1 inhibitor-46 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1. With an EC50 value of 1.425 μM, it effectively hinders viral replication. This compound is valuable for research into HIV/AIDS and the development of therapeutic strategies to combat the virus. -
HIV-1 Inhibitor
HIV-1 inhibitor-39 (compound 3c) is a potent inhibitor of HIV-1 reverse transcriptase (RT), exhibiting an IC50 of 15.75 µM. This compound demonstrates significant antiviral activity against HIV-1, making it a valuable tool for research in HIV therapy. Additionally, while it shows cytotoxic effects in MT-4 cells with a CC50 of 112.9 µM, its efficacy in inhibiting viral replication positions it as a promising candidate for further investigation in HIV-related studies. -
HIV-1 Inhibitor
HIV-1 inhibitor-30 is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an EC50 of 40 nM and an IC50 of 80 nM. This compound exhibits significant antiviral activity against various non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1 strains, with IC50 values ranging from 0.04 to 1.42 μM. HIV-1 inhibitor-30 is a valuable tool for studying HIV/AIDS pathogenesis and developing therapeutic strategies against resistant viral strains. -
HIV-1 Inhibitor
HIV-1 inhibitor-22 is a potent non-nucleoside reverse transcriptase (RT) inhibitor targeting HIV-1. It demonstrates significant antiretroviral activity, exhibiting IC50 values of 3.63 μM against HIV-1 RT and EC50 values of 0.304 μM and 0.201 μM against HIV-1 wild-type and K103N strains, respectively. Additionally, HIV-1 inhibitor-22 shows low cytotoxicity, with a CC50 greater than 227 μM, making it a valuable tool for investigating HIV-1 replication and resistance mechanisms in research applications. -
HIV-1 Entry Inhibitor
Myriceric acid B is a potent HIV-1 entry inhibitor that specifically targets the gp41 protein. This compound exhibits antiviral activity by preventing the fusion of the viral and host cell membranes, thereby inhibiting viral entry. Additionally, Myriceric acid B demonstrates antitumor properties, making it a valuable candidate for research in virology and cancer biology. -
HIV-1 RT Inhibitor
BM 21.1298 is a selective non-nucleoside inhibitor of HIV-1 reverse transcriptase (RT), targeting the viral replication process. This compound exhibits significant antiviral activity, making it a valuable tool for research in HIV pathogenesis and treatment strategies. BM 21.1298's specificity towards HIV-1 RT allows for detailed studies of enzyme function and potential therapeutic applications. -
Reverse Transcriptase Inhibitor
Dexelvucitabine is a potent nucleoside reverse transcriptase inhibitor that targets HIV-1 polymerase. This orally active compound exhibits efficacy against HIV-1 strains resistant to thymidine analogs and those harboring the M184V mutation. As a 2′-deoxycytidine analog, Dexelvucitabine serves as an important research tool for studying antiretroviral therapies and the mechanisms of drug resistance in viral infections. -
HIV-1 Reverse Transcriptase Inhibitor
Thiazolobenzimidazole is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. It effectively inhibits HIV-induced cytotoxicity and viral replication in various human cell lines, making it a valuable compound for research on HIV therapy and antiviral drug development. Its mechanism of action offers insights into potential therapeutic strategies against HIV-1 infection. -
HIV Fusion Inhibitor
Sifuvirtide is a potent HIV fusion inhibitor that targets the HIV-1 envelope glycoprotein, blocking the process of viral entry into host cells. This compound exhibits robust dose-dependent inhibition of HIV-1 mediated cell fusion and demonstrates high efficacy against various primary and laboratory-adapted HIV-1 isolates. Sifuvirtide is valuable for research applications focused on the development of anti-HIV therapeutics and studying viral entry mechanisms. -
HIV Entry Inhibitor
T-peptide is an HIV entry inhibitor that functions as a Tuftsin analog, effectively targeting HIV infection. This compound is known to mitigate cellular immunosuppression and enhance survival rates in septic mouse models. Additionally, T-peptide demonstrates the ability to inhibit the growth of residual tumor cells following surgical resection, making it a valuable tool for oncological and infectious disease research applications. -
HIV Inhibitor
HIV-IN-1 is a potent HIV inhibitor that specifically targets HIV replication mechanisms. This compound exhibits significant antiviral activity, making it suitable for research applications focused on understanding HIV infection and developing therapeutic strategies. Its efficacy in inhibiting viral replication positions HIV-IN-1 as a valuable tool in HIV-related studies. -
HIV-1 Inhibitor
HIV-1 Inhibitor-28 targets the HIV-1 reverse transcriptase (RT) to effectively inhibit viral replication. This compound demonstrates high potency with an EC50 of 58 nM against wild-type HIV-1 and an IC50 of 3.37 μM for HIV-1 RT, while exhibiting low cytotoxicity in MT-4 cells (CC50 = 38.6 μM). HIV-1 Inhibitor-28 is suitable for research applications focused on AIDS and the development of antiviral therapies. -
HIV-1 Inhibitor
HIV-1 inhibitor-24 (compound S-12a) is a potent inhibitor of HIV-1 reverse transcriptase, demonstrating an IC50 value of 9.5 nM. This compound exhibits strong antiretroviral activity against wild-type HIV-1, with an EC50 of 1.6 nM, while maintaining a low cytotoxic profile (CC50 of 9.07 μM in MT-4 cells). In vivo studies indicate that HIV-1 inhibitor-24 is well tolerated at doses of 2 g/kg in mice and shows favorable cardiovascular safety, making it a valuable tool for HIV-1 research and potential therapeutic development. -
HIV Inhibitor
Globotriaosylceramide (porcine RBC) is a trihexosylceramide (Gb3) that serves as a natural resistance factor against HIV-1 infection. It is produced by the action of the synthesizing enzyme α-galactosyltransferase (A4GALT), which plays a critical role in conferring resistance to HIV-1. This compound is useful in research applications focused on understanding HIV-1 pathogenesis and exploring potential therapeutic strategies for HIV-1 infection. -
HIV-1 Inhibitor
HIV-1 inhibitor-54 is a potent HIV-1 inhibitor that targets the viral replication process. It exhibits significant anti-HIV activity in MT-4 cells, with an EC50 value of 0.032 μM against the wild-type HIV-1 strain IIIB. This compound is suitable for research applications aimed at understanding virus infection and developing antiviral strategies. -
HIV-1 Inhibitor
CNI-H0294 hydrochloride is a selective inhibitor of HIV-1 integrase, playing a crucial role in the viral life cycle by blocking the integration of viral DNA into the host genome. This compound demonstrates potential in the study of HIV-associated central nervous system diseases and can be employed in research to explore therapeutic strategies aimed at HIV infections. Its specificity for the integrase enzyme makes it an essential tool for investigating antiviral mechanisms and developing novel HIV treatments. -
HIV-1 Inhibitor
HIV-1 inhibitor-21 is a potent non-nucleoside reverse transcriptase inhibitor targeting the HIV-1 reverse transcriptase enzyme, achieving an IC50 of 0.55 μM. This compound exhibits significant antiretroviral activity against both HIV-1 wild-type and K103N strains, with EC50 values of 12.7 nM and 10.4 nM, respectively. Notably, HIV-1 inhibitor-21 demonstrates low cytotoxicity, with a CC50 of 10.2 μM in MT-4 cells, making it a valuable candidate for HIV research and therapeutic exploration. -
HIV Inhibitor
HIV-IN-3 is a potent inhibitor of HIV, exhibiting an IC50 of 1.5 μM. This compound effectively disrupts HIV replication, making it a valuable tool for studies related to HIV infections and HIV-related disease mechanisms. Its potent activity supports various research applications aimed at developing therapeutic strategies against HIV. -
HIV-1 Inhibitor
A3N19 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1, demonstrating an EC50 of 3.28 nM against the HIV-1 IIIB strain. This compound effectively inhibits viral replication, making it a valuable tool for research focused on HIV-1 pathogenesis and therapeutic development. Its high potency makes A3N19 suitable for detailed studies in antiviral drug efficacy and resistance mechanisms. -
HIV Inhibitor
Antiviral agent 55 is a potent inhibitor of human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2), demonstrating significant antiviral activity. It is particularly useful in research applications focused on HIV replication and pathogenesis, offering insights into potential therapeutic interventions against these viral infections. This compound allows for the exploration of antiviral mechanisms and supports the development of effective treatments for HIV. -
HIV RT Inhibitor
(+)-Carbovir triphosphate is a potent inhibitor and substrate for HIV reverse transcriptase. This nucleotide analogue effectively impedes viral replication by interfering with the reverse transcription process. It is utilized in research applications focused on HIV drug development and the mechanistic study of reverse transcriptase inhibition. -
HIV-1 Inhibitor
HIV-1 inhibitor-25 (compound R-12a) is a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an IC50 value of 0.1061 μM. This compound demonstrates significant antiretroviral activity against wild-type HIV-1, with an EC50 of 13.6 nM, while maintaining low cytotoxicity (CC50 of 33.13 μM) in MT-4 cells. Additionally, HIV-1 inhibitor-25 shows inhibitory effects on various HIV-1 mutant strains, presenting EC50 values ranging from 0.1961 to 5.8136 μM. This reagent is valuable for research focused on HIV/AIDS therapies. -
Reverse Transcriptase Inhibitor
(+)-Dihydrocalanolide A is a non-nucleoside inhibitor of Reverse Transcriptase, exhibiting oral bioactivity. This compound demonstrates significant inhibitory effects on HIV replication and is valuable in research investigating HIV infection mechanisms and potential therapeutic strategies. Its pharmacological profile supports its use in studies aimed at understanding antiviral activities and developing new HIV treatments. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-6 is a potent inhibitor of HIV-1 protease, demonstrating an impressive IC50 of 21 pM and a Ki of 4.7 pM. This compound displays significant antiviral activity against darunavir-resistant variants, surpassing that of the wild type virus. Its high potency and efficacy make it a valuable tool for researching HIV-1 replication and resistance mechanisms. -
HIV-1 RT Inhibitor
Calcium mesoxalate is an inhibitor of HIV-1 reverse transcriptase (RT) with an IC50 value of 2.2 μM. This compound demonstrates significant antiviral activity, making it a valuable tool for researchers studying HIV-1 replication mechanisms and potential therapeutic interventions. Its application in the investigation of HIV-1 RT’s role in viral propagation can aid in the development of novel antiviral strategies. -
HIV-1/microtubule Inhibitor
Wikstrol B is a biflavonoid that acts as an inhibitor of microtubule polymerization and HIV-1 replication. It demonstrates an IC50 value of 184 μM for microtubule inhibition and an EC50 of 3.02 μM against HIV-1, affecting early replication processes. Additionally, Wikstrol B displays antifungal activity by inducing morphological changes in Pyricularia oryzae hyphae and exhibits anti-mitotic properties. This compound is valuable for research into antifungal, antitumor, and anti-HIV therapeutic applications. Naturally extracted from the roots of Wikstroemia indica, it offers a unique avenue for investigations in these domains. -
HIV Inhibitor
KP-1212 is a nucleoside analog that functions as an HIV inhibitor through the mechanism of mutagenizing the viral genome. This unique action compromises viral replication, effectively inhibiting HIV growth. KP-1212 is primarily utilized in research focusing on antiviral drug development and the mechanisms of HIV pathogenesis. -
HIV Inhibitor
GPS491 is an HIV inhibitor that targets the regulation of viral RNA expression. With an EC50 value of 0.47 μM, GPS491 effectively suppresses the expression of the HIV-1 structural protein Gag and modifies the accumulation of HIV-1 RNA. This compound decreases the levels of RNA encoding structural proteins while enhancing the abundance of regulatory protein RNAs, making it a valuable tool for studying HIV biology and potential therapeutic interventions. -
HIV-1 Inhibitor
HIV-1 inhibitor-32 is a potent inhibitor targeting HIV-1, demonstrating an IC50 value of 34 nM against wild-type HIV-1. This compound is valuable for investigating pathways of HIV replication and can assist in the development of therapeutic strategies for AIDS research. Its efficacy makes it a crucial tool for studies aimed at understanding HIV-1 pathogenesis and treatment options. -
HIV-1 Inhibitor
HIV-1 inhibitor-55 is a potent inhibitor targeting wild-type HIV-1, exhibiting an EC50 value of 8.6 nM. This compound also displays significant inhibitory activity against both single and double HIV-1 mutants, making it a valuable tool for studying viral resistance mechanisms. HIV-1 inhibitor-55 is applicable in research focused on HIV-1 infection and potential therapeutic interventions. -
HIV-1 Inhibitor
PF-46396 is a potent inhibitor of HIV-1, exhibiting an effective concentration (EC50) of 0.206 µM. It demonstrates significant antiviral activity by inhibiting the processing of the capsid (CA) and spacer peptide 1 (SP1) from the Gag precursor proteins. This blockade effectively disrupts the maturation of the viral core particle, making PF-46396 a valuable tool for research in HIV-1 mechanisms and potential therapeutic interventions. -
HIV-1 Inhibitor
HIV-1 Inhibitor-52 is a potent inhibitor targeting the HIV-1 virus, demonstrating broad-spectrum antiviral activity. With effective concentrations (EC50) ranging from 1.6 nM to 6.4 nM against a variety of wild-type and mutant strains, including HIV-1 V370A and HIV-1 T332S/V362I/prR41G, this compound is valuable for research into HIV-1 pathways. It serves as a critical tool for studies focused on the mechanisms of HIV resistance and potential therapeutic strategies. -
HIV-1 Capsid Inhibitor
HIV-1 Inhibitor-18 is a potent inhibitor specifically targeting the HIV-1 capsid with an EC50 value of 5.14 μM against HIV-1 NL4-3. This compound displays cytotoxicity, showing an MT-4 cell CC50 greater than 9.51 μM. It serves as a valuable tool for researching HIV-1 replication mechanisms and potential therapeutic interventions against HIV-1 infection. -
HIV-1 Inhibitor
HIV-1 inhibitor-14 is a potent non-nucleoside reverse transcriptase (RT) inhibitor targeting HIV-1. It demonstrates strong inhibitory activity with an EC50 of 0.14 μM against HIV-1 RT and is effective against both wild-type and resistant strains, with EC50 values ranging from 5.79 to 28.3 nM. This compound is valuable for research applications focused on understanding HIV-1 resistance mechanisms and developing antiviral therapies. -
HIV-1 gp120 Inhibitor
gp120-IN-2 is a potent inhibitor of the HIV-1 gp120 protein, exhibiting an IC50 of 7.5 µM while demonstrating a CC50 of 112.93 µM. This compound effectively inhibits HIV-1 replication, showcasing anti-HIV-1 activity. Additionally, gp120-IN-2 exhibits dose-dependent cytotoxicity in SUP-T1 cells, making it a valuable tool for studying HIV-1 and potential therapeutic interventions. -
HIV-1 Inhibitor
U-89360E is a selective inhibitor of HIV-1 protease, demonstrating potent activity against the wildtype strain as well as the V82D and V82N mutants, with inhibitory constants (Ki) of 20 nM, 560 nM, and 2100 nM, respectively. Its effectiveness against multiple viral variants makes it a valuable tool for antiviral research and the development of therapeutic strategies targeting HIV-1. U-89360E is particularly relevant for studies focusing on resistance patterns and protease inhibition in the context of HIV treatment. -
HIV-1 Inhibitor
HIV-1 Inhibitor-23 is a potent non-nucleoside reverse transcriptase inhibitor targeting HIV-1. It exhibits effective inhibition with EC50 values of 24.9 nM for wild-type HIV-1 and 10.4 nM for the HIV-1 K103N mutant. Additionally, HIV-1 Inhibitor-23 demonstrates low cytotoxicity with a CC50 exceeding 221 μM and displays favorable stability in vitro under microsomal conditions, making it a valuable tool for HIV research and drug development. -
HIV-1 Protease Inhibitor
L 694746 is a potent inhibitor of HIV-1 protease, demonstrating an IC50 value of 1 nM and a Ki of 0.34 nM. This compound exhibits strong antiviral activity, making it a valuable reagent in the study of HIV replication and resistance mechanisms. Its effectiveness in inhibiting protease activity underscores its potential applications in HIV research and therapeutic development. -
HIV-1 Inhibitor
DMJ-I-228 is a CD4-mimetic compound that targets HIV-1 by binding to the gp120 protein within the conserved Phe 43 cavity, which is adjacent to the CD4-binding site. This interaction effectively obstructs the binding of CD4, leading to the inhibition of HIV-1 infection. DMJ-I-228 is utilized in research focused on HIV-1 entry mechanisms and the development of antiviral therapies. -
HIV Protease Inhibitor
DMP-851 is a potent cyclic urea inhibitor of HIV protease, exhibiting a Ki of 0.021 nM. It demonstrates significant antiviral activity against both laboratory strains of HIV-1 and HIV-2, as well as primary clinical isolates that are resistant to Zidovudine. This compound serves as an important tool for research into HIV treatment and resistance mechanisms. -
HIV Inhibitor
DAPD-NHc-pr is an HIV inhibitor that demonstrates potent antiviral activity with EC50 and EC90 values of 0.85 μM and 13 μM, respectively. This compound exhibits minimal toxicity to normal cells, including peripheral blood mononuclear cells (PBM), CEM, and VERO cell lines. DAPD-NHc-pr is valuable for studying HIV replication and exploring potential therapeutic strategies against HIV infection. -
HIV Protease Inhibitor
BILA 1906 BS is a potent HIV protease inhibitor that disrupts HIV-1 replication by inhibiting the protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. This compound effectively blocks the maturation of p24 proteins in wild-type HIV-1, thereby impairing polyprotein processing and viral maturation. BILA 1906 BS is valuable for research focused on human immunodeficiency virus type 1 (HIV-1) infection and its associated cellular mechanisms. -
HIV Inhibitor
HIV-1 inhibitor-72 is a potent inhibitor targeting the HIV-1 virus. Its primary mechanism involves binding to essential viral proteins, effectively inhibiting viral replication. This compound is valuable for research in virology and HIV-related studies, particularly in the development of therapeutics aimed at eradicating HIV-1 infection. -
HIV-1 Inhibitor
HIV-1 inhibitor-27 is a potent inhibitor targeting HIV-1, exhibiting IC50 values of 16 μM, 0.5 μM, and 0.39 μM against HIV-1 YU2, NL4-3, and 89.6 strains, respectively. This compound demonstrates low cytotoxicity, with a CC50 of 128 μM in TZM-bl cells. HIV-1 inhibitor-27 is suitable for research applications focused on understanding and combating AIDS-related mechanisms. -
HIV-1 Inhibitor
(+)-PM 92131 is a non-nucleoside inhibitor of HIV-1 that specifically targets viral replication. It demonstrates significant anti-HIV-1 activity with EC50 values of 0.8 μM and 0.6 μM against the HIV-1 RF strain, as evidenced by XTT cytoprotection and syncytium-forming assays, respectively. This compound is suitable for research applications focused on HIV infections and the mechanisms of viral inhibition. -
HIV-1 Reverse Transcriptase Inhibitor
L 697661 is an orally active inhibitor of HIV-1 reverse transcriptase, targeting the essential enzyme required for the replication of the virus. This compound demonstrates potent antiviral activity against HIV-1, making it a valuable tool for research in HIV treatment and therapies. Its ability to interrupt viral replication pathways provides critical insights into antiviral drug development and therapeutic efficacy studies. -
HIV-1 Inhibitor
HIV-1 Inhibitor-26 is a potent inhibitor of HIV-1 reverse transcriptase (RT), demonstrating an IC50 value of 1.4 μM. This compound exhibits low cytotoxicity, with a CC50 of 1486 μM in peripheral blood mononuclear cells (PBMCs). HIV-1 Inhibitor-26 is suitable for research applications focused on AIDS and the mechanisms of HIV replication. -
HIV Inhibitor
Nevirapine quinone methide is an active metabolite of Nevirapine, functioning as a non-nucleoside reverse transcriptase inhibitor (NNRTI) targeting HIV-1. This compound is utilized in research to explore its antiviral properties and the mechanisms behind its associated toxicities, including severe skin and liver injuries resulting from its metabolic activation. Additionally, Nevirapine quinone methide has been identified as an inhibitor of CYP3A4, which may further elucidate its hepatic toxicity in studies focused on drug metabolism and safety. -
HIV Inhibitor
BMS-663749 lysine is a prodrug of an HIV-1 attachment inhibitor that enhances the bioavailability of the parent compound upon oral administration. This compound exhibits potent antiviral activity against HIV-1 by blocking the virus's ability to bind to host cells. Research applications include studying HIV-1 entry mechanisms and exploring therapeutic strategies for HIV infection. -
HIV-1 RT Inhibitor, HIV-1 Inhibitor
S-2720 is a potent inhibitor of HIV-1 reverse transcriptase (HIV-1 RT) and effectively suppresses HIV-1 replication. It binds to overlapping sites on the enzyme, likely targeting a pocket within the p66 subunit, which is critical for reverse transcription. As a quinoxaline derivative, S-2720 demonstrates significant potential for advancing research in HIV-1 infection and developing therapeutic strategies against this virus.
